Alkermes reports net income for Q3, provides guidance for 2013
Feb 04, 2013 (Datamonitor via COMTEX) --
Alkermes plc, a biopharmaceutical company, has reported that net income for the third quarter ended December 31, 2012 was $16.26 million, or $0.12 per diluted share, compared to a net loss of $14.83 million, or $0.11 loss per diluted share, for the same quarter ended December 31, 2011. The company expects GAAP net income to range from break-even to positive $15 million, or a basic and diluted EPS of approximately $0.00 to $0.11.
Total revenues for the third quarter of fiscal 2013 were $135.91 million, compared to $125.64 million for the same quarter of fiscal 2012.
Net income for the nine months ended December 31, 2012 was $21.98 million, or $0.16 per diluted share, compared to a net loss of $50.32 million, or $0.46 loss per diluted share, for the same period ended December 31, 2011.
Total revenues for the nine months ended December 31, 2012 were $412.13 million, compared to $259.50 million for the same period ended December 31, 2011.
The company expects total revenues to range from $520 million to $545 million, up from a range of $510 million to $540 million.
"This quarter demonstrates the strength of Alkermes' business model, which is characterized by two robust portfolios - our commercial products and our development pipeline. The quarterly financial results underscore our ability to hit financial goals while investing in a promising pipeline," commented Richard Pops, CEO of Alkermes. "As we move into 2013, we are excited by how our late-stage pipeline is taking shape, with interesting new medicines that have blockbuster potential and many important data readouts this year."
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
[ Back To TMCnet.com's Homepage ]